Medrad chief executive Witmer to retire

Medrad announced this month that its president and CEO Thomas Witmer is planning to retire. Witmer has led the Indianola, PA, manufacturer of contrast injection systems for the last 16 years, and saw the company through its acquisition by German contrast agent developer Schering in 1995 (SCAN 8/30/95). Medrad senior vice president and general manager John Friel has been tapped to replace Witmer as president and CEO in a transition process to be phased in over the next several months. Witmer will remain on Medrad's board.